Pfizer Inc and BioNTech SE have proposed to authorities to expand their Phase 3 COVID-19 vaccine trial to approximately 44,000 participants while increasing the diversity of the trial population. The initial target figure for the covid vaccine trial that the two companies are jointly developing was up to 30,000 participants, …
Read More »